Celldex Therapeutics Inc’s filing revealed that its PRESIDENT & CEO Marucci Anthony S acquired Company’s shares for reported $0.31 million on Nov 11 ’24. In the deal valued at $26.82 per share,11,500 shares were bought. As a result of this transaction, Marucci Anthony S now holds 40,284 shares worth roughly $0.84 million.
Then, Martin Samuel Bates sold 17,172 shares, generating $608,315 in total proceeds. Upon selling the shares at $35.42, the SVP AND CFO now owns 28,125 shares.
Before that, Crowley Elizabeth sold 30,000 shares. Celldex Therapeutics Inc shares valued at $1,045,962 were divested by the SR. VP & CPDO at a price of $34.87 per share. As a result of the transaction, Crowley Elizabeth now holds 9,074 shares, worth roughly $0.19 million.
Morgan Stanley initiated its Celldex Therapeutics Inc [CLDX] rating to an Overweight in a research note published on March 20, 2025; the price target was $46. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. Citigroup began covering CLDX with “Buy” recommendation on October 07, 2024. Goldman started covering the stock on September 30, 2024. It rated CLDX as “a Neutral”.
Price Performance Review of CLDX
On Monday, Celldex Therapeutics Inc [NASDAQ:CLDX] saw its stock jump 5.80% to $20.78. Over the last five days, the stock has gained 2.11%. Celldex Therapeutics Inc shares have fallen nearly -17.77% since the year began. Nevertheless, the stocks have fallen -50.70% over the past one year. While a 52-week high of $47.00 was reached on 01/08/25, a 52-week low of $18.61 was recorded on 03/04/25. SMA at 50 days reached $22.19, while 200 days put it at $30.12.
Levels Of Support And Resistance For CLDX Stock
The 24-hour chart illustrates a support level at 20.13, which if violated will result in even more drops to 19.49. On the upside, there is a resistance level at 21.12. A further resistance level may holdings at 21.47. The Relative Strength Index (RSI) on the 14-day chart is 48.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.28, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 45.86%. Stochastics %K at 38.66% indicates the stock is a holding.
How much short interest is there in Celldex Therapeutics Inc?
A steep rise in short interest was recorded in Celldex Therapeutics Inc stocks on 2025-02-28, growing by 2296.0 shares to a total of 8.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 8.87 million shares. There was a rise of 0.03%, which implies that there is a positive sentiment for the stock.
